COLL News and Press, Collegium Pharmaceutical Inc. From 05/12/20

Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...

Collegium Pharmaceutical, Inc. (COLL) Q1 2020 Earnings Conference Call May 07, 2020, 04:30 AM ET Company Participants Alex Dasalla - Head, IR Joe Ciaffoni - President & CEO Paul Brannelly - CFO Scott Dreyer - Chief Commercial Officer Conference Call Participants David...

Image source: The Motley Fool. Collegium Pharmaceutical Inc   (NASDAQ: COLL) Q1 2020 Earnings Call May 7, 2020 , 4:30 p.m. ET Operator Continue reading

Collegium Pharmaceutical (NASDAQ: COLL ): Q1 GAAP EPS of $0.01 misses by $0.36 . More news on: Collegium Pharmaceutical, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

STOUGHTON, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 7, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and pro...

Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...

Investing in opioid manufacturers is an endeavor few investors wish to partake in. Between 2011 and 2017, more than 40,000 Americans died each year due to opioid overdose, which has become a full-blown public health crisis. Over 2,500 lawsuits across all 50 states  have been brought ag...

The most important thing is to survive the outbreak. Thereafter, for our portfolio to survive too so it can do well when the situation is favorable. Market Pulse The stock market remains unsettled and vulnerable to sharp declines. Over the last two weeks, the market has forcefully steppe...

Collegium Pharmaceutical ( COLL ) continues to advance toward becoming the frontrunner in responsible pain management. The company recorded almost 1M portfolio prescriptions in 2019 and increased their full-year net revenue by 6%. This growth is primarily due to the company's Xtampza ER prod...

The government cannot love you, and any politics that works on a different assumption is destined for no good. ”― Jonah Goldberg Today, we take a deeper look at a ' Tier 3 ' name that has been hit hard in the recent market meltdown triggered by Covid-19 despite several pie...